MLchartDataset catalogue

anti-EpCAM/anti-CD40 bispecific antibody KK2269

Term · Oncology and biomedicine · MLC-T-ONC-010638

A bispecific antibody directed against both the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326) and the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-EpCAM/anti-CD40 bispecific antibody KK2269, the anti-EpCAM moiety targets and binds to EpCAM expressed on tumor cells, and the agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells in the tumor microenvironment (TME). This induces EpCAM-dependent activation of CD40-mediated signaling pathways, and triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.

Table 1. Record
IdentifierMLC-T-ONC-010638
FieldOncology and biomedicine
Synonymsanti-EpCAM/CD40 bispecific antibody KK2269; anti-CD40/anti-EpCAM bispecific antibody KK2269; EpCAM x CD40 bispecific antibody KK2269; EpCAM-targeted CD40 agonist KK2269
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010638",
  "term": "anti-EpCAM/anti-CD40 bispecific antibody KK2269",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against both the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326) and the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-EpCAM/anti-CD40 bispecific antibody KK2269, the anti-EpCAM moiety targets and binds to EpCAM expressed on tumor cells, and the agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells in the tumor microenvironment (TME). This induces EpCAM-dependent activation of CD40-mediated signaling pathways, and triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.",
  "synonyms": [
    "anti-EpCAM/CD40 bispecific antibody KK2269",
    "anti-CD40/anti-EpCAM bispecific antibody KK2269",
    "EpCAM x CD40 bispecific antibody KK2269",
    "EpCAM-targeted CD40 agonist KK2269"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-epcam-anti-cd40-bispecific-antibody-kk2269/"
}

Record 1,735 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.